ChemoCentryx (CCXI) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ChemoCentryx (CCXI) Will Make CCR6 Poster Presentation at SID Annual Meeting
May 12, 2016 8:54 AM EDTChemoCentryx, Inc., (Nasdaq: CCXI) announced that preclinical data using a series of orally-available inhibitors of the chemokine receptor known as CCR6, have been selected for a poster presentation at the 2016 Society for Investigational Dermatology Annual Meeting, being held May 11-14, 2016 in Scottsdale, Arizona.
Poster Presentation:
Title: Chemokine Receptor Inhibition as a Novel Therapeutic Approach for Psoriasis (Abstract No. 521) Session Title: Poster Session I Session Date & Time: Thursday, May 12, 2016, 10:15 AM - 12:15 PM MST Location: Herberger Ballroom, The Westin Kierland Resort &... More
Vifor Pharma Licenses Marketing Rights to ChemoCentryx's (CCXI) CCX168
May 10, 2016 6:43 AM EDTVifor Pharma, a company of the Galenica Group, and ChemoCentryx, Inc. (Nasdaq: CCXI), a biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, announced today that Vifor Pharma has licensed rights to commercialize CCX168, a Complement 5a Receptor (C5aR) inhibitor ready for Phase 3 development for orphan and rare renal diseases, in Europe, Canada, Mexico, Central and South America and South... More
